{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-159026","form_type":"8-K","ticker":"STIM","cik":"0001227636","company_name":"Neuronetics, Inc.","filed_at":"2025-07-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.525639+00:00","generated_at":"2026-05-18T06:26:11.217571+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Neuronetics appoints Steven Pfanstiel as CFO; reaffirms Q2 & FY2025 guidance","bullets":["Pfanstiel named CFO effective July 15, replacing retiring Steve Furlong (through March 2026).","Pfanstiel previously CFO/COO of Marinus Pharmaceuticals; 20+ years medical device/pharma experience.","Inducement grant of 400,000 RSUs vesting over 3-4 years; base salary $480k, 50% target bonus.","Reaffirms Q2 and full-year 2025 guidance; targets positive cash flow in Q3 2025.","Outgoing CFO Furlong remains as Senior Advisor to CEO through end of March 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-159026","json":"https://secwatch.observer/filing/0001193125-25-159026.json","markdown":"https://secwatch.observer/filing/0001193125-25-159026.md","text":"https://secwatch.observer/filing/0001193125-25-159026.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1227636/000119312525159026/0001193125-25-159026-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1227636/000119312525159026/d34717d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T06:26:11.217571+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}